CE Maintains Buy Rating by Citigroup -- Price Target Lowered to

Celanese (CE) shares rose 7.5% after announcing immediate price hikes for key products in multiple regions, seen as a catalyst for margin recovery. The move is part of broader restructuring efforts, including asset sales. The company maintained its 2026 EPS guidance. The rally is company-specific, not driven by broader market trends. CE operates as a major producer of acetic acid and vinyl acetate monomer.

Celanese (CE) shares fell after the company announced immediate price hikes on key acetyl products in multiple regions. Investors reacted to potential cost pressures and demand concerns, though no changes to price targets were announced. The company's long-term strategy includes cost cuts and debt reduction, but profitability challenges and high debt levels remain risks.

KeyBanc initiated coverage on Celanese (NYSE: CE) with an overweight rating and a $57 price target, citing attractive valuation and strong free cash flow yield. The firm estimates the company has sufficient liquidity to repay debt through 2028. Celanese's Q2 2026 earnings beat estimates but revenue missed slightly, with a cautious outlook due to restructuring and leverage concerns.

Celanese (CE) is selling 19% of Nutrinova to Mitsui for $152M, reducing its stake to 11%. The sale, expected to close Q4, will help reduce debt and fund maturities, part of a $1B divestiture goal by 2027. The sold stake generated $4M in 2025 earnings, implying a 38x multiple.

Mitsui & Co. will integrate upstream operations at VP4, a German producer of key intermediates for Nutrinova's food ingredients. Mitsui will acquire an additional 19% stake in Nutrinova from Celanese, increasing its holding to 89% and making Nutrinova a consolidated subsidiary. This move aims to secure supply, improve cost competitiveness, and align with Mitsui's growth strategy in the Food Science business.

Celanese (NYSE: CE) will sell an additional 19% stake in Nutrinova to Mitsui for $152M, retaining an 11% interest. The deal supports its deleveraging plans and is expected to close in Q4. Celanese will operate a diketene facility for Nutrinova, receiving the purchase price and operating costs.